Targeting urocortin signaling pathways to enhance cardioprotection: Is it time to move from bench to bedside?

Cardiovascular Drugs and Therapy

Volumn 27, Issue 5, 2013, Pages 451-463

  Onorati, Francesco ^a   Chen Scarabelli, Carol ^b   Knight, Richard ^c   Stephanou, Anastasis ^c   Mohanti, Bibhu ^d   Santini, Francesco ^a   Tessari, Maddalena ^a   Kini, Annapoorna ^d   Narula, Jagat ^d   Saravolatz, Louis ^e   Mazzucco, Alessandro ^a   Scarabelli, Tiziano ^d,e   Faggian, Giuseppe ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cardioplegia; Cardioprotection; Ischemia reperfusion injury; Mitochondria; Urocortin

Indexed keywords

G PROTEIN COUPLED RECEPTOR; PLACEBO; PROTEIN KINASE; UROCORTIN; UROCORTIN I; UROCORTIN II;

APOPTOSIS; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG TARGETING; EXPERIMENTAL ANIMAL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART SURGERY; HEMODYNAMICS; HUMAN; KIDNEY FUNCTION; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; HUMANS; MITOCHONDRIA; MYOCARDIUM; SIGNAL TRANSDUCTION; UROCORTINS;

EID: 84885181085     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-013-6468-7     Document Type: Review

References (100)

1. Kuizon E, Pearce EG, Bailey SG, et al. Mechanisms of action and clinical implications of cardiac urocortin: a journey from the heart to the systemic circulation, with a stopover in the mitochondria. Int J Cardiol. 2009;137:189-94.
2. Davidson SM, Rybka AE, Townsend PA. The powerful cardioprotective effects of urocortin and the corticotrophin releasing hormone (CRH) family. Biochem Pharmacol. 2009;77:141-50.
3. Vale W, Spiess J, Rivier C, Rivier J. Characterisation of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981;213:1394-7.
4. Koob G, Heinrichs S. A role for corticotropin releasing factor and urocortin in behavioural responses to stressors. Brain Res. 1999;848:141-52.
5. Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med. 2001;7:605-11.
6. Lewis K, Li C, Perrin MH, et al. Identification of urocortin III, an additional member of the corticotrophin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA. 2001;98:7570-5.
7. Li C, Chen P, Vaughan J, Lee KF, Vale W. Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. Proc Natl Acad Sci USA. 2007;104:4206-11.
8. Grace CR, Perrin MH, Cantle JP, Vale WW, Rivier JE, Riek R. Common and divergent structural features of a series of corticotrophin releasing factor-related peptides. J Am Chem Soc. 2007;129:16102-14.
9. Davidson SM, Yellon DM. Urocortin: a protective peptide that targets both the myocardium and vasculature. Pharmacol Rep. 2009;61:172-82.
10. Scarabelli T, Knight R. Urocortins: take them to the heart. Curr Med Chem. 2004;2:187-96.
11. Coste SC, Kesterson RA, Heldwein KA, et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin- releasing hormone receptor-2. Nat Genet. 2000;24:403-9.
12. Grammatopoulos DK. Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction. Br J Pharmacol. 2012;166:85-97.
13. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol. 2004;37:449-71.
14. L. Cell. 1996;87:619-28.
15. Murriel CL, Mochly-Rosen D. Opposing roles of δ and εPKC in cardiac ischemia and reperfusion: targeting the apoptotic machinery. Arch Biochem Biophys. 2003;420:246-54.
16. Terada K, Kaziro Y, Satoh T. Analysis of Ras-dependent signals that prevent caspase-3 activation and apoptosis induced by cytokine deprivation in hematopoietic cells. Biochem Biophys Res Comm. 2000;267:449-55.
17. Cardone MH, Roy Y, Stennike HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318-21.
18. Brar BK, Stephanou A, Knight R, Latchman DS. Activation of protein kinase B/akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol. 2002;34:483-92.
19. Nishimoto S, Nishida E. MAPK signaling: ERK 5 versus ERK 1/2. EMBO Rep. 2006;7:782-6.
20. Hausenloy DJ, Yellon DM. New directions from protecting the heart against ischemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res. 2004;61:448-60.
21. Brar BK, Jonassen AK, Stephanou A, et al. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem. 2000;275:8508-14.
22. Janjua S, Lawrence KM, Ng LL, et al. The cardioprotective agent urocortin induces expression of CT-1. Cardiovasc Toxicol. 2003;3:255-62.
23. Brar BK, Railson J, Stephanou A, Knight RA, Latchman DS. Urocortin increases the expression of heat shock protein 90 in rat cardiac myocytes in a MEK1/2-dependent manner. J Endocrinol. 2002;172:283-93.
24. Brar BK, Jonassen AK, Egorina EM, et al. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology. 2004;145:24-35.
25. Chanalaris A, Lawrence KM, Townsend PA, et al. Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway. Biochem Biophys Res Commun. 2005;328:442-8.
26. Gray MO, Karliner JS, Mochly-Rosen D. A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. J Biol Chem. 1997;272:30945-51.
27. Ping P, Zhang J, Pierce Jr WM, Bolli R. Functional proteomic analysis of protein kinase C epsilon signaling complexes in the normal heart and during cardioprotection. Circ Res. 2001;88:59-62.
28. Jin ZQ, Zhou HZ, Zhu P, et al. Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol. 2002;282:H1970-7.
29. Bertolotto C, Maulon L, Filippa N, Baier G, Auberger P. Protein kinase C theta and epsilon promote T-cell survival by a rsk-dependent phosphorylation and inactivation of BAD. J Biol Chem. 2000;275:37246-50.
30. Baines CP, Zhang J, Wang GW, et al. Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection. Circ Res. 2002;90:390-7.
31. Lawrence KM, Kabir AM, Bellhcene M, et al. Cardioprotection mediated by urocortin is dependent on PKCepsilon activation. FASEB J. 2005;19:831-3.
32. Townsend PA, Davidson SM, Clarke SJ, et al. Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress. Am J Physiol Heart Circ Physiol. 2007;293:H928-38.
33. Sashinami H, Kageyama K, Suda T, Nakane A. Urocortin 2 suppresses host resistance to Listeria monocytogenes infection via upregulation of interleukin-10. Endocrinology. 2005;146:5003-11.
34. Cole WC, McPherson CD, Sontag D. ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Circ Res. 1991;69:571-81.
35. Lawrence KM, Chanalaris A, Scarabelli T, et al. K(ATP) channel gene expression is induced by urocortin and mediates its cardioprotective effect. Circulation. 2002;106:1556-62.
36. Lawrence KM, Scarabelli TM, Turtle L, et al. Urocortin protects cardiac myocytes from ischemia/reperfusion injury by attenuating calcium-insensitive phospholipase A2 gene expression. FASEB J. 2003;17:2313-5.
37. Barry SP, Lawrence KM, McCormick J, et al. New targets of urocortin-mediated cardioprotection. J Mol Endocrinol. 2010;45:69-85.
38. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis protein: why XIAP is the black sheep of the family. EMBO Reports. 2006;7:988-94.
39. Resch U, Schichl YM, Sattler S, De Martin R. XIAP regulates intracellular ROS by enhancing antioxidant gene expression. Biochem Biophys Res Commun. 2008;375:156-61.
40. Chen L, Kwong M, Lu R, et al. Nrfl is critical for redox balance and survival of liver cell during development. Mol Cell Biol. 2003;328:442-8.
41. Kwong M, Kan YW, Chan JY. The CNC basic leucine zipper factor, Nrfl, is essential for cell survival in response to oxidative stress-inducing agents. Role for Nrfl in gamma-gcs(l) and gss expression in mouse fibroblasts. J Biol Chemist. 1999;274:37491-8.
42. Lillig CH, Berndt C, Holmgren A. Glutaredoxin systems. Biochim Biophys Acta. 2008;1780:1304-17.
43. Nagy N, Malik G, Tosaki A, Ho YS, Maulik N, Das DK. Overexpression of glutaredoxin-2 reduces myocardial cell death by preventing both apoptosis and necrosis. J Mol Cell Cardiol. 2008;44:252-60.
44. Diebold BA, Bokoch GM. Molecular basis for Rac2 regulation of phagocyte NADPH oxidase. Nat Immunol. 2001;2:211-5.
45. Dyck JR, Loipaschuk GD. AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol. 2006;574:95-112.
46. Carvajal K, Zarrinpashneh E, Szarszoi O, et al. Dual cardiac contractile effects of the α2-AMPK deletion in low-flow ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2007;292:H3136-47.
47. Russell JC, Whiting H, Szuflita N, Hossain MA. Nuclear translocation of X-linked inhibitor of apoptosis (XIAP) determines cell fate after hypoxia ischemia in neonatal brain. J Neurochem. 2008;106:1357-70.
48. Terai K, Hiramoto Y, Masaki M, et al. AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol Cell Biol. 2005;25:9554-75.
49. Scarabelli TM, Pasini E, Stephanou A, et al. Urocortin promotes hemodynamic and bioenergetic recovery and improve cell survival in the isolated rat heart exposed to ischemia/reperfusion. J Am Coll Cardiol. 2002;40:155-61.
50. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion - a target for cardioprotection. Cardiovasc Res. 2004;61:372-85.
51. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med. 2005;15:69-75.
52. Onorati F, Renzulli A, De Feo M, et al. Does antegrade blood cardioplegia alone provide adequate myocardial protection in patients with left main stem disease? J Thorac Cardiovasc Surg. 2003;126:1345-51.
53. Scarabelli TM, Knight R, Stephanou A, et al. Clinical implications of apoptosis in ischemic myocardium. Curr Probl Cardiol. 2006;31:181-264.
54. Chen-Scarabelli C, Scarabelli TM. Turning necrosis into apoptosis: the exacting task that can enhance survival. Am Heart J. 2004;148:196-9.
55. Aebert H, Kirchner S, Keyser A, et al. Induction of early immediate genes and programmed cell death following cardioplegic arrest in human hearts. Eur J Cardiothorac Surg. 2000;18:589-93.
56. Scarabelli TM, Pasini E, Ferrari G, et al. Warm blood cardioplegic arrest induces mitochondrial-mediated cardiomyocyte apoptosis associated with increased urocortin expression in viable cells. J Thorac Cardiovasc Surg. 2004;128:364-71.
57. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM. Endogenous urocortins reduce vascular tone and renin-aldosterone/ endothelin activity in experimental heart failure. Eur Heart J. 2005;26:2046-54.
58. Giugliano GR, Giugliano RP, Gibson CM, et al. Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol. 2003;91:1055-9.
59. Ko D, Wang Y, Berger AK, et al. Nonsteroidal antiinflammatory drugs after acute myocardial infarction. Am Heart J. 2002;143:475-81.
60. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190:1733-40.
61. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-8.
62. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;144:537-47.
63. Tiefenbacher CP, Kapitza J, Dietz V, et al. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol. 2003;285:H59-64.
64. Weisman HF, Healy B. Myocardial infarct expansion, infarct extension, and reinfarction: pathophysiologic concepts. Prog Cardiovasc Dis. 1987;30:73-110.
65. Bradbury DA, Simmons TD, Slater KJ, et al. Measurement of the ADP:ATP ratio in human leukemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis. J Immunol Methods. 2000;240:79-92.
66. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM. Serine/threonine protein kinases and apoptosis. Exp Cell Res. 2000;256:34-41.
67. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000;101:660-7.
68. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-41.
69. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the proapoptotic molecule BAD. Proc Natl Acad Sci U S A. 2001;98:9666-70.
70. Tsuruta F, Masuyama N, Gotoh Y. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. J Biol Chem. 2002;277:14040-7.
71. Marzo I, Brenner C, Zamzami N, et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science. 1998;281:2027-31.
72. Weston CR, Balmanno K, Chalmers C, et al. Activation of ERK1/2 by deltaRaf-1:ER*represses Bim expression independently of the JNK or PI3K pathways. Oncogene. 2003;22:1281-93.
73. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001;98:11598-603.
74. Kennedy SG, Kandel ES, Cross TK, Hay N. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol. 1999;19:5800-10.
75. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol. 1998;60:619-42.
76. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601-5.
77. Balakirev MY, Khramtsov VV, Zimmer G. Modulation of the mitochondrial permeability transition by nitric oxide. Eur J Biochem. 1997;246:710-8.
78. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science. 1998;281:2042-5.
79. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113-51.
80. Majewski M, Nieborowska-Skorska M, Salomoni P, et al. Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res. 1999;59:2815-9.
81. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell. 1996;87:629-38.
82. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401:86-90.
83. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857-68.
84. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science. 1999;286:1358-62.
85. Rademaker MT, Charles CJ, Espiner EA, et al. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol. 2002;40:1495-505.
86. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation. 2005;112:3624-32.
87. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Urocortin 3: haemodynamic, hormonal and renal effects in experimental heart failure. Eur Heart J. 2006;27:2088-98.
88. Charles CJ, Jardine DL, Nicholls MG, Rademaker MT, Richards AM. Urocortin I exhibits potent inhibition of cardiac sympathetic nerve activity in conscious sheep. J Hypertens. 2008;26:53-60.
89. Rademaker MT, Charles CJ, Nicholls G, Richards M. Urocortin 2 sustains haemodynamic and renal function during introduction of beta-blockade in experimental heart failure. J Hypertens. 2011;29:1787-95.
90. Ng LL, Loke JW, O'Brien RJ, Squire IB, Davies JE. Plasma urocortin in human systolic heart failure. Clin Sci (Lond). 2004;106:383-8.
91. Gruson D, Ahn SA, Ketelslegers JM, Rousseau MF. Circulating levels of stress associated peptide Urocortin in heart failure patients. Peptides. 2010;31:354-6.
92. Phrommintikul A, Sivasinprasasn S, Lailerd N, Chattipakorn S, Kuanprasert S, Chattipakorn N. Plasma urocortin in acute myocardial infarction. Eur J Clin Invest. 2010;40:874-82.
93. Wright SP, Doughty RN, Frampton CM, Gamble GD, Yandle TG, Richards AM. Plasma Urocortin 1 in human heart failure. Circ Heart Fail. 2009;2:465-71.
94. Davis ME, Pemberton CJ, Yandle TG, et al. Urocortin-1 infusion in normal humans. J Clin Endocrinol Metab. 2004;89:1402-9.
95. Davis ME, Pemberton CJ, Yandle TG, et al. Effect of urocortin I infusion in humans with stable congestive cardiac failure. Clin Sci (Lond). 2005;109:381-8.
96. Davis ME, Pemberton CJ, Yandle TG, et al. Urocortin 2 infusion in healthy humans. J Am Coll Cardiol. 2007;49:461-71.
97. Davis ME, Pemberton CJ, Yandle TG, et al. Urocortin 2 infusion in human heart failure. Eur Heart J. 2007;28:2589-97.
98. Smani T, Calderon E, Rodriguez-Moyano M, Dominguez-Rodriguez A, Diaz I, Ordones A. Urocortin-2 induces vasorelaxation of coronary arteries isolated from patients with heart failure. Clin Exp Pharmacol Physiol. 2011;38:71-6.
99. Chen-Scarabelli C, Faggian G, Yuan Z, et al. Warm-blood cardioplegic arrest induces selective mitochondrial trans location of protein kinase Cε followed by interaction with 6.1 inwardly rectifying potassium channel subunit in viable myocytes overexpressing urocortin. J Thorac Cardiovasc Surg. 2009;138:1213-21.
100. Chen ZW, Huang Y, Yang Q, Li X, Wei W, He GW. Urocortin-induced relaxation in the human internal mammary artery. Cardiovasc Res. 2005;65:913-20.